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Summary. Background: RhoA is an important regulator
of platelet responses downstream of Ga13, yet we still
know little about its regulation in platelets. Leukemia-as-
sociated Rho guanine-nucleotide exchange factor (GEF
[LARG]), a RhoA GEF, is highly expressed in platelets
and may constitute a major upstream activator of RhoA.
To this end, it is important to determine the role of
LARG in platelet function and thrombosis. Methods and
results: Using a platelet-specific gene knockout, we show
that the absence of LARG results in a marked reduction
in aggregation and dense-granule secretion in response to
the thromboxane mimetic U46619 and proteinase-acti-
vated receptor 4–activating peptide, AYPGKF, but not
to adenosine diphosphate. In a ferric chloride thrombosis
model in vivo, this translated into a defect, under mild
injury conditions. Importantly, agonist-induced RhoA
activation was not affected by the absence of LARG,
although basal activity was reduced, suggesting that
LARG may play a housekeeper role in regulating consti-
tutive RhoA activity. Conclusions: LARG plays an impor-
tant role in platelet function and thrombosis in vivo.
However, although LARG may have a role in regulating
the resting activation state of RhoA, its role in regulating
platelet function may principally be through RhoA-inde-
pendent pathways, possibly through other Rho family
members.
Keywords: gene knockout; Larg protein, mouse; mouse;
platelets; RhoA protein, mouse; thrombosis.
Introduction
Platelets are critical for the formation of thrombi in blood
vessels, leading to rapid occlusion and tissue infarction. An
understanding of their function, at a molecular level, is
vital to enable a better understanding of the pathophysiol-
ogy of thrombotic ischemic disease and development of
approaches for diagnosis and management. Platelets
express multiple members of the Rho family of small
GTPases, whose role in many cell types is associated with
actin cytoskeletal rearrangements and membrane and
granule trafficking [1–4]. In turn, these GTPases are regu-
lated by the balanced activities of Rho activators, the gua-
nine nucleotide exchange factors (GEFs), and Rho
inhibitors, the GTPase activating proteins (GAPs). Oligo-
phrenin-1 has recently been shown to be an important
RhoGAP in platelets [5], but the activity of expressed Rho-
GEFs in platelets is currently sparsely reported.
The most abundantly expressed RhoGEF in platelets is
leukemia-associated RhoGEF (LARG, also known as
ARHGEF12) [6], a G protein–coupled receptor (GPCR)-
regulated GEF. Previously, RhoA has been described as
an important regulator of platelet function and develop-
ment, with the generation of a platelet-specific RhoA
knockout showing macrothrombocytopenia, reduced pla-
telet function in response to the thromboxane mimetic,
U46619, and thrombin and also reduced thrombus forma-
tion in vivo [4]. Based on the high level of LARG expres-
sion in platelets and its specificity for RhoA [7], we
hypothesized that LARG would be the principal signal
transducer from Ga13-coupled receptors to RhoA [8].
Here, we present data that demonstrate LARG is an
important regulator of platelet function and thrombosis
in vivo but suggest that agonist-induced RhoA activation
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does not primarily depend on LARG. As such, the regula-
tion of RhoA may principally be mediated by GEFs other
than LARG, and LARG may act independently of RhoA.
Methods
Mice
Mice carrying a floxed allele of the gene encoding LARG
(Arhgef12) were generated as previously described [9] and
crossed with PF4-Cre–positive mice for the generation of
platelet-specific knockouts. Studies were approved by the
local research ethics committee at the University of Bris-
tol, UK, with mice bred and maintained under the UK
Home Office project license PPL 30/2908.
Preparation of platelet-rich plasma
Platelet-rich plasma (PRP) was prepared from heparinized
blood (100 U mL1 1:10 v/v) taken via cardiac puncture
and supplemented with 10 U mL1 heparin (1:5 v/v).
Briefly, heparinized blood was spun in a fixed bucket micro-
centrifuge at 200 9 g for 5 min. The PRP and top third of
the erythrocyte layer were spun again in a swing bucket
centrifuge at 200 9 g for 6 min. PRP was standardized to
2 9 108 platelets mL1 in modified HEPES-Tyrode’s buf-
fer. The residual erythrocyte layer was spun at 1000 9 g in
a fixed bucket microcentrifuge. PPP was removed and
diluted to the same extent as the appropriate PRP.
Washed platelet preparation
Washed platelets were prepared from citrated blood (4%
sodium citrate, 1:10 v/v) taken via cardiac puncture and sup-
plemented with acid-citrate dextrose (1:7 v/v). Platelets were
pelleted from PRP in the presence of 140 nmol L1 prosta-
glandin E1 and 0.02 unit mL
1 apyrase. The platelet pellet
was the resuspended at a concentration of 2 9 108
platelets mL1 in modified HEPES-Tyrode’s buffer contain-
ing 0.02 unit mL1 apyrase. For certain assays, 10 lmol L1
indomethacin was added before and after the pelleting stage.
Western blotting
Western blotting samples were prepared from washed pla-
telet preparations. Rabbit anti-LARG (clone H70) and
rabbit anti-RhoA (clone 26C4) were from Insight
Biotechnology (Wembley, UK). Mouse anti–a-tubulin
was from Sigma UK (Poole, UK).
Flow cytometry
Washed platelets at 2 9 107 platelets mL1 were incu-
bated with 1/25 dilution from stock of FITC-conjugated
rat anti-mouse antibodies against CD41/aIIb, glycoprotein
(GP)VI, and GPIba or isotype-specific controls, for
10 min at room temperature, before fixation with an equal
volume of 4% paraformaldehyde. Samples were analyzed
on a BD FACS Canto II flow cytometer (BD Biosciences,
Oxford, UK) with FACS Diva software.
Lumiaggregometry
Lumiaggregometry was performed on a ChronoLog
Corp. Model 560-VS aggregometer and Aggrolink 5 soft-
ware (Lab Medics, Abingdon On Thames, UK). Manu-
facturer’s instructions were followed, with the exception
that the aggregations were scaled down to 250 lL. Maxi-
mum extent and rate of aggregation were calculated using
the Aggrolink 5 software.
Thromboxane B2 ELISA
Releasates were generated under aggregating conditions
before being quenched with 5 mmol L1 EDTA and 200
lmol L1 indomethacin. Releasates were centrifuged for
3 min at 10 000 9 g, decanted, and snap frozen. Relea-
sates were diluted 1:50 before analysis of thromboxane B2
levels via a commercial ELISA kit (Enzo Life Sciences,
Exeter, UK) according to the manufacturer’s instructions
as previously described [10].
RhoA G-LISA
Washed platelets were stimulated under non-stirring condi-
tions before the addition of an equal volume of ice-cold 29
lysis buffer (100 mmol L1 Tris-Cl, 1 mol L1 NaCl,
10 mmol L1 MgCl2, 2% Triton X-100) containing Compete,
EDTA-free protease inhibitors (Roche Diagnostics Ltd, Bur-
gess Hill, UK). Lysates were analyzed via commercial RhoA
G-LISA kit (Cytoskeleton Inc., Universal Biologicals, Cam-
bridge, UK) according to the manufacturer’s instructions.
Spreading assays
Platelets containing indomethacin at 4 9 107 platelets mL1
were added onto coverslips coated in 50 lg mL1 collagen-
related peptide or 100 lg mL1 fibrinogen, or BSA as a con-
trol, for 30 min at room temperature. Cells were fixed with
an equal volume of 8% paraformaldehyde, washed twice
with PBS, and stained with 2 lmol L1 DiOC6 for 1 h at
room temperature. Platelets were washed twice before being
mounted with MOWIOL solution containing DABCO. Pla-
telets were imaged on a Leica DM IRM epifluorescence
microscope with five random fields of view captured using
Volocity Image Analysis software (Perkin Elmer, Coventry,
UK). Images were analyzed using ImageJ 1.46.
In vivo thrombosis assays
Mice were anesthetized with 100 mg kg1 ketamine (Ve-
talar V, Pfizer) and 10 mg kg1 xylazine (Rompun,
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Bayer). Platelets were labeled by intravenous administra-
tion of 100 mg kg1 Dylight 488–conjugated anti-GPIbb
antibody (Emfret Analytics, Eibelstadt, Germany). Right
arteries were exposed, and 2 9 1-mm pads of filter paper
soaked with ferric chloride in PBS were applied for
3 min. Injury sites were imaged by time-lapse microscopy
for 20 min, and images were analyzed by ImageJ 1.46.
Background fluorescence values measured upstream of
the injury site were subtracted from the thrombus-specific
fluorescence. Data are expressed as integrated fluores-
cence density.
In vitro thrombosis assays
In vitro thrombosis assays were performed on a parallel-
plate flow chamber. Coverslips were coated with
50 lg mL1 HORM collagen for 2 h at room tempera-
ture before being blocked overnight at 4 °C with 1% fatty
Fig. 1. Leukemia-associated Rho guanine-nucleotide exchange factor (LARG)-null platelets are developmentally normal, but demonstrate
reduced activity to the thromboxane mimetic U46619 and proteinase-activated receptor 4 (PAR4) peptide AYPGKF. (A) Platelet lysates from
wild-type (WT) and knockout (KO) mice were probed via Western blotting (n = 3). (B) Platelet-rich plasma (PRP) from WT and KO mice was
analyzed via lumiaggregometry to determine (i) the maximum extent of aggregation within 3 min, (ii) the maximum rate of aggregation, and (iii)
the amount of adenosine triphosphate (ATP) secretion as a readout of dense-granule secretion (n ≥ 3). Data were compared by 2-way ANOVA with
***P < 0.001. (C) PRP from WT and KO mice was stimulated under stirring conditions for 5 min. Reactions were stopped with 5 mmol L1
EDTA and 200 lmol L1 indomethacin. Releasates were harvested via centrifugation before being analyzed for thromboxane (TX)B2 levels by
ELISA (n ≥ 3). (D) RhoA activity was measured by G-LISA. Washed platelets from WT and KO mice at 2 9 108 platelets mL1, supplemented
with 0.02 unit mL1 apyrase, were stimulated under non-stirred conditions for 5 min at 37 °C (n = 7). Data are shown as optical density (OD)
and were compared by 2-way ANOVA with *P < 0.05, **P < 0.01, and ***P < 0.001. (E) Washed platelets were applied to BSA, collagen-re-
lated peptide (CRP), or fibrinogen-coated surfaces for 1 h before fixing and staining. Adhesion was determined as being the number of adhered
platelets per field of view (i), and platelet spread area was determined by fluorescence (ii). Platelets applied to fibrinogen-coated surfaces were co-
stimulated with either 0.1 unit mL1 or 1.0 unit mL1 thrombin to stimulate spreading on that surface.
© 2015 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
Thrombosis and Haemostasis.
2104 C. M. Williams et al
acid–free BSA (Sigma, Poole, UK). Assembled chambers
were blocked for 30 min at room temperature before a
run. Blood was taken into 4% citrate (1:10 v/v) supple-
mented with 2 units mL1 heparin and 40 lmol L1
PPACK. Blood was incubated with 2 lmol L1 DiOC6
for 10 min at room temperature. Blood was allowed to
flow at 1000 s1 for 2 min. Images were captured by
time-lapse microscopy, with five randomly selected fields
of view captured for end-point analysis. Images were ana-
lyzed by ImageJ 1.46.
Results and discussion
Platelets from LARG:PF4-Cre+ (knockout) mice were
confirmed to be deficient in LARG, yet still expressed
wild-type levels of RhoA (Fig. 1A). Hematologic analysis
of knockout mice showed that absence of LARG from
platelets did not impair hematopoiesis. Likewise, the
absence of LARG in platelets did not affect the basal cell
surface expression of key platelet GPaIIb, GPIb, and
GPVI (Table 1). This is unlike the RhoA knockout where
a macrothrombocytopenia was present [4], indicating that
the absence of LARG, unlike RhoA, does not impact the
development and generation of platelets in vivo.
Aggregation of knockout platelets in PRP was dimin-
ished in response to the thromboxane mimetic U46619
and the protease-activated receptor 4 (PAR4) activating-
peptide (PAR4-P) AYPGKF but not to adenosine
diphosphate. Dense granule secretion, as measured by
adenosine triphosphate release in a luciferin-luciferase
assay (Fig. 1B), was also reduced in knockout platelets;
however, thromboxane generation was not (Fig. 1C). The
defect in thromboxane and PAR4-dependent responses
and not those to adenosine diphosphate suggests that
LARG is important in Ga12/13-linked GPCR responses
and not those linked to Gai/Gaq. Adhesion and spreading
of LARG-deficient platelets on fibrinogen or collagen-re-
lated peptide (CRP) under static conditions were also
normal (Fig. 1E), suggesting that LARG does not act
downstream of aIIbb3 integrin–associated Ga13[11].
Importantly, RhoA activity was reduced in knockout
platelets compared with wild-types in both resting and
agonist-stimulated platelets, when measured with G-LISA
(Fig. 1D). When normalized to basal activity (not
shown), there was no longer a difference in stimulated
RhoA activity between controls and LARG-deficient pla-
telets, suggesting that LARG regulates basal RhoA activ-
ity but is not critical for activating RhoA after platelet
stimulation. LARG was a good candidate to be the pri-
mary GEF regulating RhoA activity in platelets, so it is
therefore surprising that RhoA activity was not altered in
an agonist-dependent manner. It could be that LARG
plays a ‘housekeeping’ role, maintaining a background
level of RhoA activation, such that its absence results in
a cell that is less responsive, and that RhoA agonist-de-
pendent activation occurs through other RhoGEFs. The
uncoupling of the apparent functional roles of LARG
from RhoA activation may also be due to LARG regulat-
ing another Rho family member in platelets [12]. How-
ever, given that both RhoF [2] and RhoG [1,13]
knockout mice present dissimilar phenotypes, these Rho
family members are unlikely to be regulated by LARG,
suggesting that RhoB or RhoC may be involved, despite
their low copy numbers [14]. It has also been reported
that LARG can form homodimers or heterodimers with
PDZ-RhoGEF, via interactions with their inhibitory C-
terminal domains that may recruit other inhibitory factors
[15]. Although PDZ-RhoGEF is not reported to be
expressed in platelets at the protein level [14], the sugges-
tion that dimerization may recruit other inhibitory factors
could be important for explaining the regulatory role of
LARG in platelets.
Analysis of thrombus formation in vivo revealed
knockout mice were also protected from thrombosis
induced at lower (6%) concentrations of FeCl3 (Fig. 2A),
although at higher concentrations (12%) of FeCl3, this
protection was overcome (Fig. 2B). Likewise, thrombus
formation on collagen-coated surface in vitro, under non-
coagulating conditions, showed no difference between
wild-type and knockout mice (Fig. 2C). The presence of
an in vivo defect under milder injury conditions is consis-
tent with a defect in thrombin-dependent thrombus for-
mation [16]. The absence of a difference in thrombus
formation under non-coagulating conditions in vitro,
where thrombin is not generated, is also consistent with
a Ga12/13-link.
We conclude that the Rho-GEF LARG has an impor-
tant role in regulating platelet aggregation downstream of
Ga13-coupled receptors (thrombin and thromboxane
receptors). Importantly, this translates into a defect in
arterial thrombosis in vivo. Although we had hypothesized
that LARG may be operating through RhoA to mediate
Table 1 Hematology and platelet surface receptor analysis
WT KO
Mean SEM n Mean SEM n
Hematology
WBC* (103 mm3) 7.26 0.70 11 5.73 0.70 11
RBC† (106 mm3) 10.13 0.19 11 10.18 0.24 11
PLT‡ (103 mm3) 749.6 47.2 11 804.0 56.9 11
MPV§ (lm3) 5.32 0.15 11 5.26 0.06 11
Surface receptors
GPaIIb 3127 115 4 3139 212 5
GPIb 713.8 53.6 4 754.5 49.2 5
GPVI 320.9 9.7 4 325.8 11.7 5
Hematology data of citrated whole blood were acquired using a
Horiba Pentra ES60. Platelet surface receptors were determined by
flow cytometry. Washed platelets from wild-type (WT) and knockout
(KO) mice were incubated with fluorescently conjugated antibodies
against GPaIIb, GPIb, and GPVI and then fixed. Data are presented
as geometric means. *White blood cells. †Red blood cells. ‡Platelets.
§Mean platelet volume.
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these effects, the difference in phenotypes between
LARG-deficient and RhoA-deficient platelets and our dis-
covery here that only basal RhoA activity is affected by
absence of LARG points to other pathways that LARG
may regulate to mediate its effects. Given the marked
effect on dense granule secretion, we suggest that LARG
may be operating as a novel regulator of secretion down-
stream of Ga13-coupled receptors.
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Fig. 2. Mice with leukemia-associated Rho guanine-nucleotide exchange factor (LARG)-null platelets demonstrate reduced thrombus forma-
tion in response to low-level injury in vivo. Exposed carotid arteries from wild-type (WT) and knockout (KO) mice were injured with (A)
6% (WT n = 10, KO n = 11) or (B) 12% ferric chloride (WT n = 8, KO n = 6) for 3 min. Thrombus formation was monitored for
20 min. Data were analyzed using ImageJ 1.46, yielding (i) the mean integrated fluorescence density over time and (ii) the thrombus size
after 20 min. Representative images of thrombi from (iii) WT and (iv) KO. Data were compared by unpaired t-test where appropriate.
*P < 0.05. (C) Whole blood was flowed through a parallel-plate flow chamber over a collagen-coated surface. Platelet accumulation was fol-
lowed for 2 min by time-lapse microscopy (i) with still images taken for end point analysis (ii). Representative images of thrombi from (iii)
WT and (iv) KO.
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